The Class A β-Lactamase Produced by Burkholderia Species Compromises the Potency of Tebipenem against a Panel of Isolates from the United States

Tebipenem-pivoxil hydrobromide, an orally bioavailable carbapenem, is currently in clinical development for the treatment of extended-spectrum β-lactamase- and AmpC-producing Enterobacterales. Previously, tebipenem was found to possess antimicrobial activity against the biothreat pathogens, Burkhold...

Descripción completa

Detalles Bibliográficos
Autores principales: Becka, Scott A., Zeiser, Elise T., LiPuma, John J., Papp-Wallace, Krisztina M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137479/
https://www.ncbi.nlm.nih.gov/pubmed/35625319
http://dx.doi.org/10.3390/antibiotics11050674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137479/
https://www.ncbi.nlm.nih.gov/pubmed/35625319
http://dx.doi.org/10.3390/antibiotics11050674

Ejemplares similares